Camizestrant with Kisqali is effective and tolerable for ER-positive/HER2-negative advanced breast cancer, with a median PFS of 8.1 months for both doses. Objective ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Kisqali has shown to improve survival in advanced breast cancer; Ibrance has not. While early data had indicated a medicine like Ibrance, known as a CDK 4/6 inhibitor, should work in HER2 ...

The DDFS with Kisqali was consistent across all pre-specified patient subgroups, including those with node-negative (N0) disease 1. These late-breaking data are being presented at the 2024 San Antonio ...

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

Kisqali shows promise in HR-positive, HER2-negative early breast cancer, with significant invasive disease-free survival rates in the NATALEE trial. The FDA approved Kisqali for high-risk early breast ...

Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

Tumor cells circulating in the blood are the 'germ cells' of breast cancer metastases. They are very rare and could not be propagated in the culture dish until now, which made research into therapy ...

In 2023, the global breast cancer drug market is projected to be worth USD 10,733.1 million.  Between 2023 and 2033, the demand for breast cancer drugs is expected to expand at a CAGR of 1.1%, ...

On the tennis court, the results show that Gabriela Dabrowski had a successful 2024. The Canadian won the end-of-season WTA ...

The Canadian was diagnosed in April 2024 and delayed some of her treatment to play Wimbledon and the Olympic Games.

"On the heels of its U.S. FDA and EMA approvals in early breast cancer, it is encouraging to see the continued benefit of adding Kisqali to standard endocrine therapy to help reduce the risk of ...